Discovery of novel aspartyl ketone dipeptides as potent and selective caspase-3 inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 3, 2004, Pages 805-808

  Han, Yongxin ^a   Giroux, André ^a   Grimm, Erich L ^a   Aspiotis, Renée ^a   Francoeur, Sébastien ^a   Bayly, Christopher I ^a   Mckay, Daniel J ^a   Roy, Sophie ^a   Xanthoudakis, Steve ^a   Vaillancourt, John P ^a   Rasper, Dita M ^a   Tam, John ^a   Tawa, Paul ^a   Thornberry, Nancy A ^b   Paterson, Erin P ^b   Garcia Calvo, Margarita ^b   Becker, Joseph W ^b   Rotonda, Jennifer ^b   Nicholson, Donald W ^a   Zamboni, Robert J ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID DERIVATIVE; CASPASE 3 INHIBITOR; DIPEPTIDE DERIVATIVE; KETONE DERIVATIVE;

ARTICLE; COMBINATORIAL CHEMISTRY; DRUG DETERMINATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INACTIVATION; ENZYME INHIBITION; MOLECULAR MODEL; STRUCTURE ANALYSIS;

EID: 1342314180     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2003.10.064     Document Type: Article

References (22)

1. Hengartner M.O. Nature. 407:2000;770.
2. Nicholson D.W. Cell Death Differ. 6:1999;1028.
3. Thornberry N.A., Rano T.A., Peterson E.P., Rasper D.M., Timkey T., Garcia-Calvo M., Houtzager V.M., Nordstrom P.A., Rpy S., Champman K.T., Nicholson D.W. J. Biol. Chem. 272:1997;11907.
4. Kuida K., Zheng T.S., Na S., Kuan C., Yang D., Karasuyama H., Rakic P., Flavell R.H. Nature. 384:1996;368.
5. Porter A.G., Janicke R.U. Cell Death Differ. 6:1999;99.
6. Talanian R.V., Brady K.D., Cryns V.L. J. Med. Chem. 43:2000;3351.
7. Hotchkiss R.S., Chang K.C., Swanson P.E., Tinsley K.W., Hui J.J., Klender P., Xantoudakis S., Roy S., Black C., Grimm E., Han Y., Nicholson D.W., Karl I.E. Nat. Immun. 1:2000;496, and references cited therein.
8. Cheng Y., Deshmukh M., D'Costa A., Demaro J.A., Gidday J.M., Shah A., Sun Y., Jacquin M.F., Johnson E.M., Holtzman D.M. J. Clin. Invest. 101:1998;1992.
9. Schotte P., Declercq W., van Huffel S., Vandenabeele P., Beyaert R. FEBS Lett. 442:1999;117.
10. Nicholson D.W., Ali A., Thornberry N.A., Vaillancourt J.P., Ding C.K., Gallant M., Gareau Y., Griffin P.R., Labelle M., Lazebnik Y.A., Munday N.A., Raju M.S., Smulson M.E., Yamin T.-T., Yu V.L., Miller D.K. Nature. 376:1995;37.
11. Isatin analogues were reported to be selective caspase3/7 inhibitors (see: Lee, D.; Long, S. A.; Adams, J. L.; Chan, G.; Vaidya, K. S.; Francis, T. A.; Kirly, K.; Winkler, J. D.; Sung, C.-M.; Debouck, C.; Richardson, S.; Levy, M. A.; DeWolf, W. E., Jr.; Keller, P. M.; Tomaszek, T.; Head, M. S.; Ryan, M. D.; Haltiwanger, R. C.; Liang, P.-H.; Jan, C. A.; McDevitt, P. J.; Johanson, K. ; Concha, N. O.; Chan, W.; Abdel-Meguid, S. S.; Badger, A. M.; Lark, M. W.; Nadeau, D. P.; Suva, L. J.; Gowen, M.; Nutall, M. E. J. Biol. Chem. 2000, 275, 16007). These compounds have potential drawbacks due to the high reactivity of the ketone carbonyl group.
12. Grimm, E.; Renaud, J.; Aspiotis, R.; Zamboni, R. WO 00/3262, June 8, 2000; Chem. Abstr. 2002:618121.
13. Aspiotis, R.; Bayly, C. I.; Becker, J.; Ethier, D.; Francoeur, S.; Margarita, G.-C.; Giroux, A.; Grimm, E.; Han, Y.; McKay, D. J.; Nicholson, D. W.; Paterson, E.; Rasper, D.; Renaud, J.; Retonda, J.; Roy, S.; Tam, J.; Tawa, P.; Thornberry, N.; Vaillancourt, J.; Xanthoudakis, S.; Zamboni, R. Abstracts of Papers, 224th ACS National Meeting, Boston, MA, USA, Aug. 18-22, 2002.
14. 1′ position greatly affected the activity, selectivity and reversibility of casp-1 inhibitors; see: Brady K.D., Giegel D.A., Grinnell C., Lunney E., Talanian R.V., Wong W., Walker N. Bioorg. Med. Chem. 7:1999;621.
15. Graczyk P.P. Restorative Neurol. Neurosci. 14:1999;1, and references cited therein.
16. Ketone N was prepared according to the literature procedure, see: Dolle R.E., Hoyer D., Prasad C.V.C., Schmidt S.J., Helaszek C.T., Miller R.E., Ator M.A. J. Med. Chem. 37:1994;563.
17. A similar strategy using a carbazate linker has been reported, see: Lee A., Huang L., Ellman J.A. J. Am. Chem. Soc. 121:1999;9907.
18. For the preparation of the Boc protected Webb linker 1, see: Webb T.R. J. Am. Chem. Soc. 114:1992;3156.
19. Nicolaou K.C., Xiao X.-Y., Parandoosh Z., Senyei A., Nova M.P. Angew. Chem., Int. Ed. Engl. 34:1995;2289.
20. The potency of compounds to inhibit camptothecin induced apoptotic cell death in the neuronal precursor (NT2) cells was determined as described by the testing kit from Roche Molecular Biochemicals, Cat. No. 1,920,685.
21. Castrol J.L., Matassa V.G., Ball R.G. J. Org. Chem. 59:1994;2289.
22. Becker, J. W.; Rotonda, J.; Margarita, G.-C.; Bayly, C. I.; McKay, D. J. ; Paterson, E.; Thornberry, N.; Giroux, A.; Grimm, E.; Han, Y.; Francoeur, S.; Renaud, J. J. Med. Chem., submitted for publication.